EIF2AK2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon5 and 1 bp insertion in exon5.
Images
Key facts
- Cell type
- A549
- Species or organism
- Human
- Tissue
- Lung
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon5 and 1 bp insertion in exon5.
Alternative names
Double stranded RNA activated protein kinase;, E2AK2_HUMAN, EIF2AK1, EIF2AK2, Eukaryotic translation initiation factor 2-alpha kinase 2, HGNC:9437, Interferon inducible elF2 alpha kinase, Interferon-induced, double-stranded RNA-activated protein kinase, Interferon-inducible RNA-dependent protein kinase, MGC126524, P1/eIF-2A protein kinase, PPP1R83, PRKR, Protein kinase RNA-activated, Protein kinase interferon inducible double stranded RNA dependent, Protein phosphatase 1 regulatory subunit 83, Serine/threonine protein kinase TIK, Tyrosine protein kinase EIF2AK2, eIF-2A protein kinase 2, p68 kinase
What's included?
Recommended products
EIF2AK2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon5 and 1 bp insertion in exon5.
Key facts
- Cell type
- A549
- Species or organism
- Human
- Tissue
- Lung
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon5 and 1 bp insertion in exon5.
- Disease
- Carcinoma
- Concentration
Properties
- Gene name
- EIF2AK2
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing, Western blot
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 1 US: 1
- Adherent/suspension
- Adherent
- Gender
- Male
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Western blot - Human EIF2AK2 (PKR) knockout A549 cell lysate (ab256900)
Lane 1:Wild-type A549 cell lysate (20 ug)
Lane 2:EIF2AK2 knockout A549 cell lysate (20 ug)
Lane 3:K-562 cell lysate (20 ug)Anti-PKR antibody [YE350] ab32052 was shown to specifically react with PKR in wild-type A549 cells. Loss of signal was observed when knockout cell line Human EIF2AK2 (PKR) knockout A549 cell line ab266999 (knockout cell lysate ab256900) was used. Wild-type and PKR knockout samples were subjected to SDS-PAGE. Anti-PKR antibody [YE350] ab32052 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated at room temperature for 2.5 hours at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-PKR antibody [YE350] (Anti-PKR antibody [YE350] ab32052) at 1/1000 dilution
Lane 1: Wild-type A549 cell lysate at 20 µg
Lane 2: EIF2AK2 knockout A549 cell lysate at 20 µg
Lane 2: Western blot - Human EIF2AK2 (PKR) knockout A549 cell line (Human EIF2AK2 (PKR) knockout A549 cell line ab266999)
Lane 3: K-562 cell lysate at 20 µg
SecondaryAll lanes: Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) at 1/10000 dilution
Predicted band size: 62 kDa
Observed band size: 70 kDa
Sanger Sequencing - Human EIF2AK2 (PKR) knockout A549 cell lysate (ab256900)
Allele-1: 1 bp deletion in exon5
Sanger Sequencing - Human EIF2AK2 (PKR) knockout A549 cell lysate (ab256900)
Allele-2: 1 bp insertion in exon5
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com